Tag: DDD

Spine BioPharma completes US$13m Series B financing round

Spine BioPharma, a biopharmaceutical company that aims to develop non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain...

DiscGenics reveals positive interim data of cell therapy for degenerative disc...

DiscGenics has announced positive interim data from its ongoing phase 1/2 clinical trial of IDCT (rebonuputemcel), an allogeneic injectable discogenic cell therapy for degenerative...

Companion Spine raises US$55 million to further develop and market its...

Companion Spine has raised US$55 million in a Series A financing round, with the money going towards the development and commercialisation of its range...

Precision Spine launches the Dakota ACDF standalone system

Precision Spine has announced the launch of the Dakota ACDF standalone system for the treatment of degenerative disc disease (DDD). The Dakota ACDF system features...

Spinal Stabilization Technologies receives CE Mark and FDA breakthrough designation for...

Spinal Stabilization Technologies (SST) has announced that it has earned the CE Mark and the FDA's breakthrough designation for its PerQdiscâ„¢ Nucleus Replacement System...

Cerapedics granted breakthrough device designation for P-15L bone graft

Cerapedics has announced that it has been granted breakthrough device designation by the US Food and Drug Administration (FDA) for its investigational P-15L bone...